Published in Zh Mikrobiol Epidemiol Immunobiol on September 29, 2008
[Activity of a series of amino acids as potential sensitizers of smooth muscle beta-receptors]. Dokl Akad Nauk (1998) 1.56
[The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever]. Vopr Virusol (1994) 1.24
[Development and study of the properties of immunoglobulin against Ebola fever]. Vopr Virusol (1996) 1.19
DNA from Drosophila melanogaster beta-heterochromatin binds specifically to nuclear lamins in vitro and the nuclear envelope in situ. Gene (1996) 1.08
[Developing principles for emergency prevention and treatment of Ebola fever]. Vopr Virusol (1997) 1.03
[The isolation of hyperimmune horse serum to the Ebola virus]. Vopr Virusol (1994) 1.02
A new transposable element in Chironomus thummi. Mol Gen Genet (1990) 0.85
[Chemotherapy for Bolivian hemorrhagic fever in experimentally infected guinea pigs]. Vopr Virusol (2009) 0.79
[The antibody spectrum after the inoculation of sensitive animals with Yersinia pestis and Yersinia pseudotuberculosis bacteria]. Zh Mikrobiol Epidemiol Immunobiol (1996) 0.79
[Study of efficacy of modern fluoroquinolones against agent of glanders in experiments in vivo]. Zh Mikrobiol Epidemiol Immunobiol (2009) 0.79
[Development and study of properties of immunoglobulins against Lassa fever]. Vopr Virusol (1997) 0.78
[Therapeutic efficacy of Ingavirin, a new domestic formulation against influenza A virus (H3N2)]. Antibiot Khimioter (2008) 0.78
A molecular and cytogenetic analysis of lambda 20p7 fragment DNA from the proximal beta-heterochromatin of Drosophila melanogaster. Gene (1993) 0.78
[Use of guinea pigs to evaluate the efficacy of a heterological immunoglobulin against Bolivian hemorrhagic fever]. Vopr Virusol (2009) 0.78
[Evaluation of the hydrophobicity of bacterial cells by measuring their adherence to chloroform drops]. Mikrobiologiia (2002) 0.78
[Toxicity estimation of unspecific medicinal antiviral agents for prophylaxis and therapy of hazard and especially hazard viral infections]. Antibiot Khimioter (2009) 0.77
[Ribavirin prophylaxis and therapy of experimental West Nile fever]. Antibiot Khimioter (2009) 0.77
[Preparation of hyperimmune horse serum against Ebola virus]. Vopr Virusol (1995) 0.77
[In vitro efficacy of ingavirin against the Mexican pandemic subtype H1N1 of influenza A virus, strains A/California/04/2009 and A/California/07/2009]. Antibiot Khimioter (2009) 0.77
[Experimental assessment of the possible significance of argasid ticks in preserving the natural foci of West Nile virus infection]. Med Parazitol (Mosk) (2013) 0.77
[The laboratory diagnosis of an outbreak of hemorrhagic fever at Oblivskaya village, Rostov Province: proof of the etiological role of the Crimean-Congo hemorrhagic fever virus]. Zh Mikrobiol Epidemiol Immunobiol (2000) 0.77
[A trial to produce an inactivated Lassa fever vaccine]. Vopr Virusol (1994) 0.76
[Hemorrhagic (Marburg, Ebola, Lassa, and Bolivian) fevers: epidemiology, clinical pictures, and treatment]. Vopr Virusol (2006) 0.76
[Design of equine serum-based Marburg virus immunoglobulin]. Vopr Virusol (2008) 0.76
[Investigation of prophylactic activity of Ingavirin, a new Russian drug, against grippe A virus (H3N2)]. Antibiot Khimioter (2008) 0.76
[Use of guinea pigs for assessing the efficacy of vaccines against Lassa fever]. Vopr Virusol (2004) 0.76
Development of monoclonal antibodies to highly pathogenic avian influenza H5N1 virus and their application to diagnostics, prophylaxis, and therapy. Acta Virol (2011) 0.75
[Prophylactic and therapeutic efficacies of Ingavirin, a novel Russian chemotherapeutic, with respect to influenza pathogen A (H5N1)]. Antibiot Khimioter (2010) 0.75
[Study of immunogenicity and protective efficacy of a novel inactivated vaccine with chitosan against influenza A/H1N1/2009]. Zh Mikrobiol Epidemiol Immunobiol (2012) 0.75
[Fluoroquinolones: antimicrobial activity and chemotherapeutic efficacy with respect to various pathogens in highly dangerous diseases]. Antibiot Khimioter (2007) 0.75
[Estimation of in vitro Monclavit-1 virucide activity against influenza virus A (H5N1)]. Antibiot Khimioter (2010) 0.75
[The time course of changes in cell immunological parameters during administration of live dry plague vaccine]. Klin Lab Diagn (2009) 0.75
[Experimental study of sensitivity of probiotic microorganisms to antibacterial drugs]. Eksp Klin Gastroenterol (2011) 0.75
[Cowpox: features of spread after cancellation of mandatory pox immunization]. Zh Mikrobiol Epidemiol Immunobiol (2012) 0.75
[Study of Ingavirin antiviral activity against Mexican pandemic influenza virus A/H1N1/2009 in vitro and in vivo]. Antibiot Khimioter (2010) 0.75
[New immunoglobulin for treatment of anthrax]. Zh Mikrobiol Epidemiol Immunobiol (2009) 0.75
[Comparative assessment of survival of probiotic microorganisms from commercial preparations under the conditions in vitro]. Eksp Klin Gastroenterol (2011) 0.75
[Current problems of microorganisms physiology]. Zh Evol Biokhim Fiziol (2004) 0.75
[Standardization of conditions for the evaluation of effectiveness of antibacterial drugs in pneumonic plague in sacred baboons]. Antibiot Khimioter (1995) 0.75
[Experience with empirical treatment of severe acute respiratory syndrome due to coronavirus, genotype IV]. Antibiot Khimioter (2011) 0.75
[Prophylaxis of the experimental pseudotuberculosis infection by immunization with porin from Yersinia pseudotuberculosis]. Biull Eksp Biol Med (1999) 0.75
[Experimental study of Grippferon antiviral activity against Mexican pandemic influenza virus A/H1N1/2009 in vitro]. Antibiot Khimioter (2011) 0.75
[In vitro activity of Ingavirin against influenza virus A (H3N2)]. Antibiot Khimioter (2009) 0.75
[Cytological classification of nontoxic nodular goiter]. Klin Lab Diagn (2008) 0.75
[Improvement of a procedure for detection and identification of Bacillus anthracis by means of dry nutrient media]. Klin Lab Diagn (2006) 0.75
[Rift valley fever]. Zh Mikrobiol Epidemiol Immunobiol (2012) 0.75
[Genotyping of the Bacillus anthracis vaccine strains using the multiloci VNTR-analysis]. Mol Gen Mikrobiol Virusol (2009) 0.75
[Detection of mycotoxin T2 with different solid-phase enzyme immunoassays]. Klin Lab Diagn (2009) 0.75
[Identification of clinical isolates of Burkholderia cepacia and assessment of their pathogenicity in animal experiments]. Zh Mikrobiol Epidemiol Immunobiol (2008) 0.75
[The experimental evaluation with flow cytofluorimetry technique of the level of cellular immunologic memory in persons vaccinated against plague and anthrax]. Klin Lab Diagn (2013) 0.75
[In vitro Ingavirin efficacy against adenoviral infection pathogen]. Antibiot Khimioter (2009) 0.75
[Argentine hemorrhagic fever]. Zh Mikrobiol Epidemiol Immunobiol (2012) 0.75
[Effect of antibacterial therapy on the epidemic threat of experimental pneumonic plague in monkeys]. Antibiot Khimioter (2001) 0.75
[Evaluation of the protection efficiency of secretory antibodies in experimental Yersinia infection in guinea-pigs immunized with polyvalent vaccine against this infection]. Patol Fiziol Eksp Ter (2010) 0.75
[Relationship between the level of serum rearrangement of vaccinated animals and the stress of immunity to experimental plague]. Klin Lab Diagn (2007) 0.75
[Identification of genes encoding ligninolytic enzymes in naturally occurring basidiomycete isolates]. Prikl Biokhim Mikrobiol (2013) 0.75
[Assessment of immunity and allergy after vaccination with dry combined anthrax vaccine]. Zh Mikrobiol Epidemiol Immunobiol (2007) 0.75
[Survival of probiotic microorganisms in the conditions in vitro imitating the process of human digestion]. Eksp Klin Gastroenterol (2011) 0.75
[Triazavirin prophylactic efficacy against influenza virus A (H5N1)]. Antibiot Khimioter (2010) 0.75
[Experience with use of immunomodulators in treatment of tonsillitis developed at the background of preimmunization by TEOVac]. Antibiot Khimioter (2011) 0.75
[Current understanding of the pathogenesis of infectious diseases]. Vestn Ross Akad Med Nauk (2003) 0.75
[Reproductive function in female sables]. Veterinariia (1973) 0.75
[Isolation and characterization of bacterial strains resistant to arsenical compounds]. Mikrobiologiia (1996) 0.75
[In vitro investigation of Ingavirin efficacy against influenza B virus]. Antibiot Khimioter (2009) 0.75
[Stabilization of peroxidase conjugates used in enzyme immunoassay systems to detect Ebola and Marburg virus antigens]. Vopr Virusol (2010) 0.75
[The 75th anniversary of the Research Institute of Microbiology of the Ministry of Defense of the Russian Federation]. Voen Med Zh (1999) 0.75
[Interferon inductor cupping of postvaccinal complications after variolation]. Antibiot Khimioter (2010) 0.75
[Experimental study of a possibility of serodiagnosis of pseudotuberculosis in man using immunoblotting]. Biull Eksp Biol Med (1997) 0.75
[The nosological structure of the mortality of fetuses\infants with extremely low weight (acccording to the 2004-2008 records of the Kursk Regional Morbid Anatomy Bureau)]. Arkh Patol (2010) 0.75
[Use of antibiotics in the treatment of ulceronecrotic tonsillitis due to vaccination by tabletted smallpox vaccine]. Antibiot Khimioter (2010) 0.75
[Hantapulmonary syndrome]. Zh Mikrobiol Epidemiol Immunobiol (2012) 0.75
[Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1)]. Antibiot Khimioter (2011) 0.75
[Monkeypox: features of spread after cancellation of mandatory pox immunization]. Zh Mikrobiol Epidemiol Immunobiol (2012) 0.75
[Yersinia pestis superoxide dismutase]. Vestn Ross Akad Med Nauk (1995) 0.75
[Immunochemical methods for the diagnosis of pseudotuberculosis (a review of the literature)]. Klin Lab Diagn (1995) 0.75
[An experimental model of pseudotuberculosis infection in monkeys]. Biull Eksp Biol Med (1994) 0.75
[The development and testing of a molecular biological test system for DNA detection of anthrax pathogen by real-time polymerase chain reaction assay]. Klin Lab Diagn (2011) 0.75
[Bolivian hemorrhagic fever]. Zh Mikrobiol Epidemiol Immunobiol (2013) 0.75
[Current laboratory methods to evaluate the efficiency of immunization against dangerous and extremely dangerous infections]. Klin Lab Diagn (2011) 0.75
[Biological and physico-chemical properties of Yersinia pseudotuberculosis bacterial culture having the fra-operon Yersinia pestis]. Mol Gen Mikrobiol Virusol (2008) 0.75
[Evaluation of safety of prophylactic use of immunoglobulins against viral hemorrhagic fevers from horse blood sera]. Zh Mikrobiol Epidemiol Immunobiol (2013) 0.75
[Treatment of late stages of anthracic infection]. Antibiot Khimioter (2007) 0.75
[Isolation and identification of Actinomyces bovis bacteria in purulent infections of mixed etiology]. Klin Lab Diagn (2008) 0.75
[Present state of in vitro and in vivo studies on efficacy of medical nonspecific protective agents with respect to genotype IV coronavirus causing severe acute respiratory syndrome]. Antibiot Khimioter (2011) 0.75
[The role of the Yersinia plasmid of calcium-dependency in the formation of the plague immunity]. Mol Gen Mikrobiol Virusol (2005) 0.75
[INTESTINAL FAILURE AND YERSINIA PSEUDOTUBERCULOSIS TRANSLOCATION IN THE DEVELOPMENTOF EXPERIMENTAL GENERALIZED INFECTION]. Eksp Klin Gastroenterol (2016) 0.75
[Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture]. Antibiot Khimioter (2007) 0.75